Table III.
Association of ZNF382 expression and promoter methylation with Kaplan-Meier survival in the 105 pediatric AML samples.
| Variable | No. of patients | Over survival Median ± SE | P-value |
|---|---|---|---|
| Cytogenetics | |||
| Favorable | 50 | 46.664±3.717 | <0.001 |
| Intermediate | 27 | 29.220±3.188 | |
| Unfavorable | 28 | 11.161±1.827 | |
| FAB score | |||
| M1-M6 | 93 | 36.113±2.885 | <0.001 |
| M7 | 12 | 8.542±1.820 | |
| Leukocytes (/μl) | |||
| >10,000 | 61 | 30.220±2.974 | 0.803 |
| ≤10,000 | 44 | 33.631±4.063 | |
| MRD | |||
| <0.25% | 49 | 53.627±3.151 | <0.001 |
| ≥0.25% | 56 | 18.893±2.425 | |
| ZNF382 expression | |||
| Low <4.03 | 52 | 32.020±3.661 | 0.283 |
| High ≥4.03 | 53 | 31.571±3.306 | |
| ZNF382 methylation | |||
| Negative | 77 | 34.215±3.236 | 0.346 |
| Positive | 28 | 28.051±4.275 | |
ZNF382, zinc finger protein 382; FAB, French-American-British classification; AML, acute myeloid leukemia; MRD, minimal residual disease.